...
首页> 外文期刊>Scientific reports. >The prognostic significance of MRI-detected extramural venous invasion, mesorectal extension, and lymph node status in clinical T3 mid-low rectal cancer
【24h】

The prognostic significance of MRI-detected extramural venous invasion, mesorectal extension, and lymph node status in clinical T3 mid-low rectal cancer

机译:临床T3中低直肠癌中MRI检测到的副检测静脉侵袭,中脉络延伸和淋巴结状态的预后意义

获取原文

摘要

The purpose of this study was to evaluate the prognostic significance of the magnetic resonance imaging-detected extramural venous invasion (MR-EMVI), the depth of mesorectal extension (MR-DME), and lymph node status (MR-LN) in clinical T3 mid-low rectal cancer. One hundred and forty-six patients with clinical T3 mid-low rectal cancer underwent curative surgery were identified. Pretreatment high-resolution MRI was independently reviewed by two experienced radiologists to evaluate MR-EMVI score (0-4), MR-DME (≤4?mm or 4?mm), and MR-LN (positive or negative). The Cox-multivariate regression analysis revealed that the MR-EMVI was the only independent prognostic factor that correlated with overall 3-year disease-free survival (DFS) (p?=?0.01). The survival analysis showed that patients with positive MR-EMVI, MR-DME??4?mm, and positive MR-LN had a poorer prognosis in the overall 3-year DFS (HR 3.557, 95% CI 2.028 to 13.32, p??0.01; HR 3.744, 95% CI:1.165 to 5.992, p?=?0.002; HR 2.946, 95% CI: 1.386 to 6.699, p??0.01). By combining MR-EMVI with MR-DME or MR-LN, the prognostic significance was more remarkable. Our study suggested that the MR-EMVI, MR-DME, and MR-LN were the important prognostic factors for patients with clinical T3 mid-low rectal cancer and the MR-EMVI was an independent prognostic factor.
机译:本研究的目的是评估磁共振成像检测到的副静脉侵袭(MR-EMVI),介性延伸(MR-DME)深度和淋巴结状态(MR-LN)的预后意义,临床T3中低直肠癌。鉴定了一百四十六名临床T3中低直肠癌患者进行了治疗手术。预处理高分辨率MRI由两位经验丰富的放射科医生独立审查,以评估MR-EMVI评分(0-4),MR-DME(≤4Ω·mm或>4Ωmm)和MR-LN(正面或阴性)。 COX-多变量的回归分析显示MR-EMVI是唯一与总体3年无病生存(DFS)相关的独立预后因素(P?= 0.01)。生存分析表明,阳性MR-EMVI的患者,MR-DME MR-DME ??> 4?mm,阳性MR-LN在整个3年DFS中预后较差(HR 3.557,95%CI 2.028至13.32,P ?<?0.01; HR 3.744,95%CI:1.165至5.992,P?= 0.002; HR 2.946,95%CI:1.386至6.699,P?<?0.01)。通过将MR-EMVI与MR-DME或MR-LN组合,预后显着性更为显着。我们的研究表明,MR-EMVI,MR-DME和MR-LN是临床T3中低直肠癌患者的重要预后因素,而MR-EMVI是一个独立的预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号